Sign In
Buy BDSX
$16.10
+0.660 (+4.27%)
At Close: Jun 03, 2026
Biodesix CEO Scott Hutton Selected as One of Top 25 Biotech CEOs of 2021
06:30am, Thursday, 25'th Feb 2021
BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology
Biodesix to Participate in Two February Conferences
06:30am, Friday, 12'th Feb 2021
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two
Biodesix Publishes Data on New COVID-19 Artificial Intelligence (AI)-Based Algorithm for Use in Clinical Decision Support Systems
06:30am, Tuesday, 09'th Feb 2021
BOULDER, Co.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development
Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine
07:30am, Tuesday, 02'nd Feb 2021
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutt
Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference
06:30am, Tuesday, 26'th Jan 2021
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clin
U.S. IPO Week Ahead: The IPO Market Takes A Break During The Shortened Holiday Week
12:35pm, Sunday, 22'nd Nov 2020
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 m
Biodesix: Challenged From The Start
04:22pm, Sunday, 01'st Nov 2020
Biodesix has gone public in an offering which was not well-received by the market. Lack of growth and steep losses make investors rightfully cautious based on the conditions as they are today.
